6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study
Smit, E, Reck, M, Krzakowski, M, Gridelli, C, Curescu, S, Berzinec, P, Barata, F, McDermott, R, Jovanovic, D, Magyar, P
Published in European journal of cancer supplements (2007)
Published in European journal of cancer supplements (2007)
Get full text
Journal Article
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer
Scheusan, R., Curescu, S., Stanculeanu, D., Curescu, P.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
Brugger, W., Triller, N., Blasinska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G., Mazieres, J., Whittom, R., Rohr, K., Cappuzzo, F.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article